Previous studies investigating the effects of adjuvant : allergen fusion proteins, including TLR5-, TLR7-, and TLR9-ligands, on the modulation of allergen-specific immune responses demonstrated the potential for such conjugate vaccines to improve allergy treatment [13–16]. The gene discussed is TLR5; the disease is allergic disease.